Inhibrx Reports Third Quarter 2026 Financial Results

Inhibrx posts rising losses and debt as clinical programs advance but revenue remains minimal.

What the company is saying

Inhibrx Biosciences, Inc. reports progress on two lead clinical programs, ozekibart (INBRX-109) and ordastobart (INBRX-106), emphasizing upcoming data presentations and regulatory milestones. The company highlights a planned data update for ozekibart in Ewing sarcoma at the CTOS meeting in Seoul, South Korea, on November 19-20, 2026, and ongoing commercial readiness for ozekibart in chondrosarcoma. For ordastobart, Inhibrx is enrolling the Phase 2 HexAgon study in HNSCC and expects a mid-2027 readout, with plans to align with the FDA and initiate Phase 3 thereafter. The narrative stresses strategic positioning in HPV-positive HNSCC and the potential for broader solid tumor indications. Financial commentary explains that R&D expenses fell due to lower clinical trial costs and headcount, while G&A expenses rose with pre-commercialization spending. The company attributes a sharp increase in other expenses to higher interest on a $275.0 million loan balance. The tone is factual, with forward-looking statements about regulatory and clinical milestones but no overstatement of near-term commercial impact.

What the data suggests

Financial results show Inhibrx remains in a pre-commercial stage with minimal revenue and significant losses. Revenue for Q3 2026 was $2.0 million, entirely from a non-exclusive patent license to Pfizer, with no product sales. R&D expenses declined year-over-year from $28.5 million to $26.0 million, reflecting lower clinical trial costs and headcount, but were offset by increased contract manufacturing for regulatory filings. G&A expenses rose from $5.3 million to $7.8 million, driven by pre-commercialization activities. Other expenses surged to $7.0 million from $1.4 million, as interest expense grew due to a jump in outstanding debt from $100.0 million to $275.0 million. Net loss widened to $38.7 million ($2.46 per share) from $35.3 million ($2.28 per share) in the prior year quarter. As of September 30, 2026, cash and cash equivalents stood at $199.5 million, but the company had total liabilities of $306.2 million and a stockholders’ deficit of $85.9 million. Operationally, both lead programs are in mid-to-late clinical development, but no efficacy or enrollment data are disclosed, and all major milestones are at least several months away.

Analysis

The announcement is a standard quarterly update from a clinical-stage biotech, with a neutral tone and no exaggerated language. The majority of the operational claims are factual and supported by detailed financial disclosures, including net loss, cash position, and expense breakdowns. Forward-looking statements (e.g., clinical trial timelines, commercial readiness, and regulatory plans) are typical for the sector and are not presented with undue certainty or hype. The company is incurring significant R&D and pre-commercialization expenses, and its long-term debt has increased substantially, indicating high capital intensity with no immediate revenue or profit impact. While the company highlights upcoming milestones, these are appropriately caveated as future events, and there is no evidence of narrative inflation. The gap between narrative and evidence is minimal, as the company does not overstate the imminence or certainty of future benefits.

Risk flags

• ●The company’s financial position is deteriorating, with net loss increasing to $38.7 million in Q3 2026 and a stockholders’ deficit of $85.9 million as of September 30, 2026. This raises concerns about future funding needs and dilution risk.
• ●Long-term debt has nearly tripled year-over-year to $276.7 million, resulting in a sharp rise in interest expense and total liabilities of $306.2 million. High leverage limits financial flexibility and increases insolvency risk if clinical or regulatory milestones are delayed.
• ●Operational execution risk is elevated, as both lead programs are still in clinical development with no disclosed efficacy or enrollment data, and all major value inflection points are at least several months to years away. Failure to achieve positive clinical outcomes or regulatory approvals would jeopardize the path to commercialization.
• ●The company’s revenue remains negligible and entirely non-recurring, with $2.0 million in Q3 2026 from a single patent license to Pfizer. There is no evidence of sustainable revenue generation, making the business model highly dependent on future clinical and regulatory success.
• ●Pre-commercialization spending is increasing, as shown by the rise in G&A expenses, but there is no guarantee that these investments will translate into approved products or meaningful market access. If regulatory timelines slip or commercial uptake is weak, sunk costs could further erode shareholder value.

Bottom line

Inhibrx is advancing two late-stage clinical programs but remains a high-risk, capital-intensive biotech with no product revenue and widening losses. The company’s cash position of $199.5 million is offset by $276.7 million in long-term debt and a stockholders’ deficit, with interest expense now a major drag on results. All major clinical and regulatory catalysts are months to years away, and the only near-term event is a data presentation at CTOS in South Korea. The absence of disclosed enrollment or efficacy data leaves the true progress of the pipeline unclear. Investors should recognize that the business is highly leveraged to future clinical success, and any setbacks could require additional dilutive financing or trigger financial distress. The most important takeaway is that while pipeline progress continues, the financial trajectory is negative and the timeline to potential value realization remains long.

Announcement summary

(NASDAQ:INBX) Inhibrx Biosciences, Inc. reported financial results for the third quarter of 2026. The company has two programs in ongoing clinical trials: ozekibart (INBRX-109) and ordastobart (INBRX-106). Inhibrx plans to present updated results from the Phase 1/2 study of ozekibart (INBRX-109) in combination with irinotecan and temozolomide in refractory Ewing sarcoma at the Connective Tissue Oncology Society (CTOS) meeting in Seoul, South Korea from November 19th-20th, 2026. Commercial readiness activities for ozekibart in chondrosarcoma are advancing in line with the regulatory review timeline. The company is enrolling the Phase 2 portion of the randomized HexAgon study of ordastobart (INBRX-106) in head and neck squamous cell carcinoma (HNSCC) in combination with pembrolizumab, which is expected to add approximately 50 additional HPV-positive Oropharyngeal Squamous Cell Carcinoma patients. The initial readout of the Phase 2 expansion is expected around mid-2027, after which the company plans to align with the FDA and anticipates initiating the Phase 3 portion of the HexAgon trial as the confirmatory study. Initial results from the Phase 1/2 study of ordastobart (INBRX-106) in perioperative non-small cell lung cancer (NSCLC) are expected in mid-2027. As of September 30, 2026, Inhibrx had cash and cash equivalents of $199.5 million. The company recognized $2.0 million of revenue during the third quarter of 2026 under a license agreement with Pfizer, Inc., for a non-exclusive license of certain patent rights, with the $2.0 million upfront payment received in September 2026. Research and development expenses were $26.0 million for the third quarter of 2026, compared to $28.5 million for the third quarter of 2025, primarily due to decreased clinical trial costs and headcount, partially offset by increased contract manufacturing expenses. General and administrative expenses were $7.8 million during the third quarter of 2026, compared to $5.3 million during the third quarter of 2025, mainly due to additional pre-commercialization expenses. Total other expense was $7.0 million during the third quarter of 2026, compared to $1.4 million during the third quarter of 2025, primarily due to higher interest expense on the company's $275.0 million outstanding loan balance versus $100.0 million in the prior year period. Net loss was $38.7 million during the third quarter of 2026, or $2.46 per share, basic and diluted, compared to a net loss of $35.3 million, or $2.28 per share, in the third quarter of 2025. For the nine months ended September 30, 2026, total revenue was $2.0 million, research and development expenses were $75,082,000, general and administrative expenses were $21,729,000, total operating expenses were $96,811,000, total other expense was $14,010,000, provision for income taxes was $3,000, and net loss was $108,824,000, or $6.95 per share. As of September 30, 2026, total assets were $220,291,000, current liabilities were $27,302,000, long-term debt was $276,701,000, total liabilities were $306,167,000, and stockholders' deficit was $85,876,000.

Disagree with this article?